世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

バイオマーカー市場：タイプ別（検証、有効性、安全性）、疾患別（神経疾患、癌、免疫疾患、心血管疾患、その他）、用途別（個別化治療薬、創薬開発、診断薬、その他） - 2030年までの世界産業分析、動向、成長、セグメント別予測、地域別展望 世界予測


Biomarkers Market by Type (Validation, Efficacy, and Safety), By Disease (Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, and Others), By Application (Personalized Medicines, Drug Discovery & Development, Diagnostics, and Others) - Global Industry Analysis, Trends, Growth, Segment Forecasts, Regional Outlook Global Forecast up to 2030

世界のバイオマーカー市場は、主に慢性疾患の有病率の上昇と、プロテオミクスやゲノミクスなどのオミクス技術の進歩によって牽引されている。バイオマーカーとして知られる生物学的指標は、疾病診断、疾病進行追... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
IHR Insights
アイエイチアールインサイト 		2023年11月13日 US$4,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		76 英語

　

サマリー

世界のバイオマーカー市場は、主に慢性疾患の有病率の上昇と、プロテオミクスやゲノミクスなどのオミクス技術の進歩によって牽引されている。バイオマーカーとして知られる生物学的指標は、疾病診断、疾病進行追跡、治療効果評価に使用される。医薬品の研究および発見におけるバイオマーカーの利用の増加は、予測期間中に世界的な市場拡大を促進すると予想される。
バイオマーカー市場のプレーヤーにチャンスをもたらしている注目すべき要素には、バイオマーカー研究イニシアティブへの資金提供の増加、非侵襲的診断検査のニーズの拡大などがある。しかし、新規バイオマーカーに基づく診断・治療アプローチを構築するには、コストと時間がかかる可能性がある。そのため、中小企業にとってはバイオマーカーに基づく検査や治療へのアクセスが難しくなる可能性がある。
バイオマーカー市場の主な成長分野の一つは、がん、心臓病、神経疾患、感染症などの慢性疾患の有病率の上昇である。
世界保健機関（WHO）の推計によると、がんを主な原因の一つとする慢性疾患は、世界全体の死亡者数の約71％を占めている。
病気を診断し治療するためには、バイオマーカーが不可欠である。バイオマーカーに基づく診断と治療の必要性は、慢性疾患の有病率の上昇によって高まっている。
この調査研究には、企業の年次報告書、プレスリリース、投資家向けプレゼンテーション、ホワイトペーパー、認定出版物、評判の高い著者による記事、ゴールド・スタンダードとシルバー・スタンダードを満たすウェブサイト、バッテリーセパレーターを製造する企業のほか、規制機関、業界ディレクトリ、データベース、著者が確認された出版物などが含まれる。二次調査は主に、業界のサプライチェーン、主要プレイヤーの総数、市場分類、地域別およびボトムレベルの市場動向によるセグメンテーションに関する重要データの収集に使用した。また、市場に焦点を当てた立場から重要な変化を知るためにも活用した。
後述する推定プロセスにより全体市場規模を算出した後、市場全体を様々なセグメントとサブセグメントに分割した。該当する場合は、市場分解とデータ三角測量技術を使用して、市場エンジニアリングプロセス全体を完成させ、各セグメントとサブセグメントの正確な統計を決定した。供給側と需要側の両方から複数の要素やパターンを調べることで、データを三角測量した。さらに、トップダウン戦略とボトムアップ戦略の両方を採用することで、市場を検証した。
調査方法
二次調査により世界のバイオマーカー市場のシナリオを基本的に理解した後、広範な一次調査を実施した。バイオマーカーを提供するティア1およびティア2企業の主要メーカー、ディストリビューター、チャネルパートナーのCレベルおよびDレベルのエグゼクティブ、プロダクトマネージャー、マーケティングおよびセールスマネージャー、学界、研究機関、CROの担当者など、供給側と需要側の業界専門家に多数の一次インタビューを実施した。これらのインタビューは5つの主要地域で行われた：北米、欧州、アジア太平洋、その他の地域（中南米、中東、アフリカ）。一次インタビューのうち、供給側と需要側の参加者は、それぞれ約70％と30％に参加した。アンケート、Eメール、オンライン調査、直接面談、電話インタビューなどを用いて、この主要データを収集した。主な参加者のシェアは以下の通りである：


製品別バイオマーカー市場
- 消耗品
- サービス
- ソフトウェア
バイオマーカーの種類別市場
- 安全性バイオマーカー
- 有効性バイオマーカー
- 予測バイオマーカー
- 代替バイオマーカー
- 薬力学バイオマーカー
- 予後予測バイオマーカー
- バリデーションバイオマーカー
用途別バイオマーカー市場
- 診断
- 創薬・医薬品開発
- 個別化医療
- 疾患リスク評価
- その他の用途
疾患別バイオマーカー市場
- 癌
- 感染症
- 免疫疾患
- 神経疾患
- 心血管疾患
- その他の疾患
バイオマーカー市場：地域別
- 北米
米国
カナダ
- 欧州
o ドイツ
o イギリス
o フランス
o イタリア
o スペイン
o 残りのヨーロッパ（RoE）
- アジア太平洋（APAC）
o 中国
o 日本
o インド
o オーストラリア
o 韓国
o その他のアジア太平洋地域（RoAPAC）
- ラテンアメリカ（LATAM）
o ブラジル
o アルゼンチン
o その他の南米諸国
- 中東・アフリカ（MEA）
o アラブ首長国連邦
o トルコ
o サウジアラビア
o 南アフリカ
o その他の中東・アフリカ

世界のタイプ別バイオマーカー市場において、2019年は安全性バイオマーカー分野がトップシェアを占めた。安全性バイオマーカーの市場シェアが大きい主な原因は、創薬プロセスにおける用途の拡大である。予測期間中、新規診断プロセスを創出するための研究開発費の増加など、他の変数が安全性バイオマーカーの使用増加につながると予測される。
予測期間中、年平均成長率（CAGR）が最も大きいのは有効性バイオマーカーであり、これは主に新製品の発売が予定されているためである。
世界で最も研究が進んでいる疾患の1つが癌である。現在進行中のがん分野の研究では、致命的な疾患の早期発見におけるバイオマーカーの応用が、がん治療の画期的な転換点になり得ることが示されている。がんバイオマーカーの主要メーカーによる強力な製品パイプラインにより、がん治療におけるこれらのツールの受容性が高まることが期待される。神経疾患分野は、今後数年間で顕著なCAGRで成長すると予想される。
バイオマーカーは臨床開発段階を拡大するのに役立つため、創薬開発におけるバイオマーカーの利用は絶えず増加している。創薬・医薬品開発分野の増加は、こうした原因によるものです。
本調査では、北米、欧州、アジア太平洋、中南米、中東、アフリカなど、いくつかの地理的地域におけるバイオマーカー製品の主な開発と動向を調査している。地理的には、北米はがん罹患率が高く、医療制度が進んでいるため、バイオマーカー市場を支配している。一方、アジア太平洋地域は、業界大手による研究開発投資の増加や、バイオ医薬品部門を支援する政府の施策により、より速い成長が見込まれている。
世界のバイオマーカー市場では、研究開発を優先する企業が上位を占めると予想される。世界のバイオマーカー市場の上位企業には、Abbott、Hoffmann-La Roche Ltd.、Johnson & Johnson Services, Inc.、Bio-Rad Laboratories, Inc.、Qiagen、Epigenomics AG、Abbott、Agilent Technologies, Inc.、Thermo Fisher Scientific, Inc.などがあります。
- 本レポートは、バイオマーカー市場の最も重要な属性を示しており、これが市場を牽引し、機会を提供しています。
- この調査レポートは、バイオマーカー市場の成長を市場のいくつかのセグメントに基づいて詳細に分析します。
- バイオマーカー市場の過去と現在の動向予測を提示します。
- また、バイオマーカー市場の主要企業の主要戦略や能力などの競争分析も提示しています。

ページTOPに戻る


目次

Table of Contents
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Product Type: Market Size & Analysis
5.1. Overview
5.2. Consumables
5.3. Services
5.4. Software
6. Type: Market Size & Analysis
6.1. Overview
6.2. Safety Biomarkers
6.3. Efficacy Biomarkers
6.4. Predictive Biomarkers
6.5. Surrogate Biomarkers
6.6. Pharmacodynamics Biomarkers
6.7. Prognostic Biomarkers
6.8. Validation Biomarkers
7. Application: Market Size & Analysis
7.1. Overview
7.2. Diagnostics
7.3. Drug Discovery & Development
7.4. Personalized Medicine
7.5. Disease Risk Assessment
7.6. Other Applications
8. Disease Indication: Market Size & Analysis
8.1. Overview
8.2. Cancer
8.3. Infectious Diseases
8.4. Immune Disorders
8.5. Neurological Disorders
8.6. Cardiovascular Disorders
8.7. Other Disease Indications

9. Geography: Market Size & Analysis
9.1. Overview
9.2. North America (U.S., Mexico, Canada)
9.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
9.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
9.5. Latin America (Brazil, Argentina)
9.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
10. Competitive Landscape
10.1. Competitor Comparison Analysis
10.2. Market Developments
10.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
10.2.2. Product Launches and execution
11. Vendor Profiles
11.1. Ge Healthcare
11.1.1. Overview
11.1.2. Financial Overview
11.1.3. Product Offerings
11.1.4. Developments
11.1.5. Business Strategy
11.2. Bio-Rad Laboratories
11.2.1. Overview
11.2.2. Financial Overview
11.2.3. Product Offerings
11.2.4. Developments
11.2.5. Business Strategy
11.3. Eisai Co. Ltd.
11.3.1. Overview
11.3.2. Financial Overview
11.3.3. Product Offerings
11.3.4. Developments
11.3.5. Business Strategy
11.4. Abbott Laboratories, Inc.
11.4.1. Overview
11.4.2. Financial Overview
11.4.3. Product Offerings
11.4.4. Developments
11.4.5. Business Strategy
11.5. Thermo Fisher Scientific Inc.
11.5.1. Overview
11.5.2. Financial Overview
11.5.3. Product Offerings
11.5.4. Developments
11.5.5. Business Strategy
11.6. Agilent Technologies Inc.
11.6.1. Overview
11.6.2. Financial Overview
11.6.3. Product Offerings
11.6.4. Developments
11.6.5. Business Strategy
11.7. Roche Diagnostics Limited
11.7.1. Overview
11.7.2. Financial Overview
11.7.3. Product Offerings
11.7.4. Developments
11.7.5. Business Strategy
11.8. Aushon Biosystem
11.8.1. Overview
11.8.2. Financial Overview
11.8.3. Product Offerings
11.8.4. Developments
11.8.5. Business Strategy
11.9. Epistem Ltd.
11.9.1. Overview
11.9.2. Financial Overview
11.9.3. Product Offerings
11.9.4. Developments
11.9.5. Business Strategy
11.10. Siemens AG
11.10.1. Overview
11.10.2. Financial Overview
11.10.3. Product Offerings
11.10.4. Developments
11.10.5. Business Strategy

12. Analyst Opinion
13. Annexure
13.1. Report Scope
13.2. Market Definitions
13.3. Research Methodology
13.3.1. Data Collation and In-house Estimation
13.3.2. Market Triangulation
13.3.3. Forecasting
13.4. Report Assumptions
13.5. Declarations
13.6. Stakeholders
13.7. Abbreviations

ページTOPに戻る



図表リスト

Tables
TABLE 1. BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 2. BIOMARKERS MARKET VALUE FOR CONSUMABLES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. BIOMARKERS MARKET VALUE FOR SERVICES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. BIOMARKERS MARKET VALUE FOR SOFTWARE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 6. BIOMARKERS MARKET VALUE FOR SAFETY BIOMARKERS, 2021-2030 (USD BILLION)
TABLE 7. BIOMARKERS MARKET VALUE FOR EFFICACY BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. BIOMARKERS MARKET VALUE FOR PREDICTIVE BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. BIOMARKERS MARKET VALUE FOR SURROGATE BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. BIOMARKERS MARKET VALUE FOR PHARMACODYNAMICS BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. BIOMARKERS MARKET VALUE FOR VALIDATION BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 13. BIOMARKERS MARKET VALUE FOR DIAGNOSTICS, 2021-2030 (USD BILLION)
TABLE 14. BIOMARKERS MARKET VALUE FOR DRUG DISCOVERY & DEVELOPMENT, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 15. BIOMARKERS MARKET VALUE FOR PERSONALIZED MEDICINE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. BIOMARKERS MARKET VALUE FOR DISEASE RISK ASSESSMENT, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 17. BIOMARKERS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 18. BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 19. BIOMARKERS MARKET VALUE FOR CANCER, 2021-2030 (USD BILLION)
TABLE 20. BIOMARKERS MARKET VALUE FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 21. BIOMARKERS MARKET VALUE FOR IMMUNE DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 22. BIOMARKERS MARKET VALUE FOR NEUROLOGICAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 23. BIOMARKERS MARKET VALUE FOR CARDIOVASCULAR DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 24. NORTH AMERICA BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 25. NORTH AMERICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 26. NORTH AMERICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 27. NORTH AMERICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 28. U.S BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 29. U.S BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 30. U.S BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 31. U.S BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 32. CANADA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 33. CANADA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 34. CANADA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 35. CANADA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 36. MEXICO BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 37. MEXICO BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 38. MEXICO BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 39. MEXICO BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 40. EUROPE BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 41. EUROPE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 42. EUROPE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 43. EUROPE BIOMARKERS MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION)
TABLE 44. EUROPE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 45. GERMANY BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 46. GERMANY BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 47. GERMANY BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 48. GERMANY BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 49. U.K BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 50. U.K BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 51. U.K BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 52. U.K BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 53. FRANCE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 54. FRANCE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 55. FRANCE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 56. FRANCE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 57. ITALY BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 58. ITALY BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 59. ITALY BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 60. ITALY BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 61. SPAIN BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 62. SPAIN BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 63. SPAIN BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 64. SPAIN BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 65. ROE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 66. ROE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 67. ROE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 68. ROE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 69. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 70. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 71. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 72. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 73. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 74. CHINA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 75. CHINA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 76. CHINA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 77. CHINA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 78. INDIA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 79. INDIA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 80. INDIA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 81. INDIA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 82. JAPAN BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 83. JAPAN BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 84. JAPAN BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 85. JAPAN BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 86. REST OF APAC BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 87. REST OF APAC BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 88. REST OF APAC BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 89. REST OF APAC BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 90. LATIN AMERICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 91. LATIN AMERICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 92. LATIN AMERICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 93. LATIN AMERICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 94. BRAZIL BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 95. BRAZIL BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 96. BRAZIL BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 97. BRAZIL BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 98. ARGENTINA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 99. ARGENTINA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 100. ARGENTINA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 101. ARGENTINA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 102. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 103. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 104. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 105. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 106. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 107. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 108. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 109. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 110. UAE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 111. UAE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 112. UAE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 113. UAE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 114. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 115. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 116. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 117. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 118. GE HEALTHCARE: FINANCIALS
TABLE 119. GE HEALTHCARE: PRODUCTS & SERVICES
TABLE 120. GE HEALTHCARE: RECENT DEVELOPMENTS
TABLE 121. BIO-RAD LABORATORIES: FINANCIALS
TABLE 122. BIO-RAD LABORATORIES: PRODUCTS & SERVICES
TABLE 123. BIO-RAD LABORATORIES: RECENT DEVELOPMENTS
TABLE 124. EISAI CO. LTD.: FINANCIALS
TABLE 125. EISAI CO. LTD.: PRODUCTS & SERVICES
TABLE 126. EISAI CO. LTD.: RECENT DEVELOPMENTS
TABLE 127. ABBOTT LABORATORIES, INC.: FINANCIALS
TABLE 128. ABBOTT LABORATORIES, INC.: PRODUCTS & SERVICES
TABLE 129. ABBOTT LABORATORIES, INC.: RECENT DEVELOPMENTS
TABLE 130. THERMO FISHER SCIENTIFIC INC.: FINANCIALS
TABLE 131. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES
TABLE 132. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
TABLE 133. AGILENT TECHNOLOGIES INC.: FINANCIALS
TABLE 134. AGILENT TECHNOLOGIES INC.: PRODUCTS & SERVICES
TABLE 135. AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS
TABLE 136. ROCHE DIAGNOSTICS LIMITED: FINANCIALS
TABLE 137. ROCHE DIAGNOSTICS LIMITED: PRODUCTS & SERVICES
TABLE 138. ROCHE DIAGNOSTICS LIMITED: DEVELOPMENTS
TABLE 139. AUSHON BIOSYSTEM: FINANCIALS
TABLE 140. AUSHON BIOSYSTEM: PRODUCTS & SERVICES
TABLE 141. AUSHON BIOSYSTEM: RECENT DEVELOPMENTS
TABLE 142. EPISTEM LTD.: FINANCIALS
TABLE 143. EPISTEM LTD.: PRODUCTS & SERVICES
TABLE 144. EPISTEM LTD.: RECENT DEVELOPMENTS
TABLE 145. SIEMENS AG: FINANCIALS
TABLE 146. SIEMENS AG: PRODUCTS & SERVICES
TABLE 147. SIEMENS AG: RECENT DEVELOPMENTS

　

ページTOPに戻る


　

Summary

The worldwide biomarkers market is primarily being driven by the rise in the prevalence of chronic diseases and the advancements in omics technologies, such as proteomics and genomics. Biological indicators known as biomarkers are employed in disease diagnosis, disease progression tracking, and therapy efficacy assessment. Increasing use of biomarkers in medication research and discovery is anticipated to fuel market expansion globally over the course of the forecast period.
Notable elements that are generating chances for biomarkers market players include the rise in funding for biomarker research initiatives and the expansion of the need for non-invasive diagnostic tests. However, it can be costly and time-consuming to create novel biomarker-based diagnostic and treatment approaches. This may make biomarker-based tests and treatments more difficult to access for smaller businesses.
One of the main growth areas for the biomarkers market is the rise in the prevalence of chronic illnesses like cancer, heart disease, neurological conditions, and infectious diseases.
The World Health Organisation (WHO) estimates that chronic illnesses—of which cancer is one of the main causes—account for roughly 71% of all fatalities globally.
In order to diagnose and cure diseases, biomarkers are essential. The need for biomarker-based diagnoses and treatments is being driven by the rise in the prevalence of chronic diseases.
This research study includes company annual reports, press releases, and investor presentations; white papers; accredited publications; and articles by reputable authors; websites that meet the gold- and silver-standards; and businesses that manufacture battery separators as well as regulatory agencies, trade directories, databases, and publications with verified authorship. Secondary research was primarily used to gather important data on the industry's supply chain, the total number of key players, market classification, and segmentation according to regional and bottom-level market trends. It has also been utilized to learn about significant changes from a market-focused standpoint.
The complete market was divided into various segments and subsegments after the estimation process described below yielded the overall market size. Where applicable, the market breakdown and data triangulation techniques were used to complete the entire market engineering process and determine the precise statistics for each segment and subsegment. By examining multiple elements and patterns from both the supply and demand sides, the data was triangulated. Additionally, the market was validated by employing both top-down and bottom-up strategies.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide biomarkers market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering biomarkers, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:


Biomarkers Market based on Product
• Consumables
• Services
• Software
Biomarkers Market based on Type
• Safety Biomarkers
• Efficacy Biomarkers
• Predictive Biomarkers
• Surrogate Biomarkers
• Pharmacodynamics Biomarkers
• Prognostic Biomarkers
• Validation Biomarkers
Biomarkers Market based on Application
• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment
• Other Applications
Biomarkers Market based on Disease Indication
• Cancer
• Infectious Diseases
• Immune Disorders
• Neurological Disorders
• Cardiovascular Disorders
• Other Disease Indications
Biomarkers Market based on Geography
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa

In the worldwide biomarkers market by type, the Safety Biomarkers segment held the leading market share in 2019. The main cause of safety biomarkers' large market share is their growing application in the drug-discovery process. During the estimate period, it is anticipated that other variables, such as increased expenditure in research and development to create novel diagnostic processes, will lead to an increase in the use of safety biomarkers.
The forecast period's largest compound annual growth rate (CAGR) is expected for efficacy biomarkers, mostly as a result of upcoming new product launches.
One of the disorders that is studied the most in the world is cancer. Ongoing studies in the field of cancer have shown that the application of biomarkers in the early identification of the fatal illness can be a game-changer for cancer treatment. It is anticipated that a strong product pipeline from leading producers of cancer biomarkers will increase the acceptance of these tools in cancer treatment. The segment for neurological diseases is expected to grow at a notable CAGR in the coming years.
Because biomarkers can help scale up the clinical development stage, their usage in drug discovery and development is constantly increasing. The rise of the drug discovery and development segment is attributed to these causes.
The study examines the main developments and trends in biomarker products in several geographic areas, such as North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Geographically, North America dominates the biomarkers market because of the region's high cancer incidence and advanced healthcare system. Conversely, Asia-Pacific is expected to grow at a faster rate because to increased investment in research & development by major industry players and government measures to support the biopharmaceutical sector.
The firms in the global biomarkers market that priorities research and development are anticipated to hold the top spot. The top players in the worldwide biomarkers market include Abbott, Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Bio-Rad Laboratories, Inc., Qiagen, Epigenomics AG, Abbott, Agilent Technologies, Inc., and Thermo Fisher Scientific, Inc.
• This report illustrates the most vital attributes of the Biomarkers Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Biomarkers Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Biomarkers Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Biomarkers Market.



ページTOPに戻る


Table of Contents

Table of Contents
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Product Type: Market Size & Analysis
5.1. Overview
5.2. Consumables
5.3. Services
5.4. Software
6. Type: Market Size & Analysis
6.1. Overview
6.2. Safety Biomarkers
6.3. Efficacy Biomarkers
6.4. Predictive Biomarkers
6.5. Surrogate Biomarkers
6.6. Pharmacodynamics Biomarkers
6.7. Prognostic Biomarkers
6.8. Validation Biomarkers
7. Application: Market Size & Analysis
7.1. Overview
7.2. Diagnostics
7.3. Drug Discovery & Development
7.4. Personalized Medicine
7.5. Disease Risk Assessment
7.6. Other Applications
8. Disease Indication: Market Size & Analysis
8.1. Overview
8.2. Cancer
8.3. Infectious Diseases
8.4. Immune Disorders
8.5. Neurological Disorders
8.6. Cardiovascular Disorders
8.7. Other Disease Indications

9. Geography: Market Size & Analysis
9.1. Overview
9.2. North America (U.S., Mexico, Canada)
9.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
9.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
9.5. Latin America (Brazil, Argentina)
9.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
10. Competitive Landscape
10.1. Competitor Comparison Analysis
10.2. Market Developments
10.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
10.2.2. Product Launches and execution
11. Vendor Profiles
11.1. Ge Healthcare
11.1.1. Overview
11.1.2. Financial Overview
11.1.3. Product Offerings
11.1.4. Developments
11.1.5. Business Strategy
11.2. Bio-Rad Laboratories
11.2.1. Overview
11.2.2. Financial Overview
11.2.3. Product Offerings
11.2.4. Developments
11.2.5. Business Strategy
11.3. Eisai Co. Ltd.
11.3.1. Overview
11.3.2. Financial Overview
11.3.3. Product Offerings
11.3.4. Developments
11.3.5. Business Strategy
11.4. Abbott Laboratories, Inc.
11.4.1. Overview
11.4.2. Financial Overview
11.4.3. Product Offerings
11.4.4. Developments
11.4.5. Business Strategy
11.5. Thermo Fisher Scientific Inc.
11.5.1. Overview
11.5.2. Financial Overview
11.5.3. Product Offerings
11.5.4. Developments
11.5.5. Business Strategy
11.6. Agilent Technologies Inc.
11.6.1. Overview
11.6.2. Financial Overview
11.6.3. Product Offerings
11.6.4. Developments
11.6.5. Business Strategy
11.7. Roche Diagnostics Limited
11.7.1. Overview
11.7.2. Financial Overview
11.7.3. Product Offerings
11.7.4. Developments
11.7.5. Business Strategy
11.8. Aushon Biosystem
11.8.1. Overview
11.8.2. Financial Overview
11.8.3. Product Offerings
11.8.4. Developments
11.8.5. Business Strategy
11.9. Epistem Ltd.
11.9.1. Overview
11.9.2. Financial Overview
11.9.3. Product Offerings
11.9.4. Developments
11.9.5. Business Strategy
11.10. Siemens AG
11.10.1. Overview
11.10.2. Financial Overview
11.10.3. Product Offerings
11.10.4. Developments
11.10.5. Business Strategy

12. Analyst Opinion
13. Annexure
13.1. Report Scope
13.2. Market Definitions
13.3. Research Methodology
13.3.1. Data Collation and In-house Estimation
13.3.2. Market Triangulation
13.3.3. Forecasting
13.4. Report Assumptions
13.5. Declarations
13.6. Stakeholders
13.7. Abbreviations

ページTOPに戻る



List of Tables/Graphs

Tables
TABLE 1. BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 2. BIOMARKERS MARKET VALUE FOR CONSUMABLES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. BIOMARKERS MARKET VALUE FOR SERVICES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. BIOMARKERS MARKET VALUE FOR SOFTWARE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 6. BIOMARKERS MARKET VALUE FOR SAFETY BIOMARKERS, 2021-2030 (USD BILLION)
TABLE 7. BIOMARKERS MARKET VALUE FOR EFFICACY BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. BIOMARKERS MARKET VALUE FOR PREDICTIVE BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. BIOMARKERS MARKET VALUE FOR SURROGATE BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. BIOMARKERS MARKET VALUE FOR PHARMACODYNAMICS BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. BIOMARKERS MARKET VALUE FOR VALIDATION BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 13. BIOMARKERS MARKET VALUE FOR DIAGNOSTICS, 2021-2030 (USD BILLION)
TABLE 14. BIOMARKERS MARKET VALUE FOR DRUG DISCOVERY & DEVELOPMENT, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 15. BIOMARKERS MARKET VALUE FOR PERSONALIZED MEDICINE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. BIOMARKERS MARKET VALUE FOR DISEASE RISK ASSESSMENT, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 17. BIOMARKERS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 18. BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 19. BIOMARKERS MARKET VALUE FOR CANCER, 2021-2030 (USD BILLION)
TABLE 20. BIOMARKERS MARKET VALUE FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 21. BIOMARKERS MARKET VALUE FOR IMMUNE DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 22. BIOMARKERS MARKET VALUE FOR NEUROLOGICAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 23. BIOMARKERS MARKET VALUE FOR CARDIOVASCULAR DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 24. NORTH AMERICA BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 25. NORTH AMERICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 26. NORTH AMERICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 27. NORTH AMERICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 28. U.S BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 29. U.S BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 30. U.S BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 31. U.S BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 32. CANADA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 33. CANADA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 34. CANADA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 35. CANADA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 36. MEXICO BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 37. MEXICO BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 38. MEXICO BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 39. MEXICO BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 40. EUROPE BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 41. EUROPE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 42. EUROPE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 43. EUROPE BIOMARKERS MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION)
TABLE 44. EUROPE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 45. GERMANY BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 46. GERMANY BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 47. GERMANY BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 48. GERMANY BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 49. U.K BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 50. U.K BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 51. U.K BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 52. U.K BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 53. FRANCE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 54. FRANCE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 55. FRANCE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 56. FRANCE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 57. ITALY BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 58. ITALY BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 59. ITALY BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 60. ITALY BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 61. SPAIN BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 62. SPAIN BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 63. SPAIN BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 64. SPAIN BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 65. ROE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 66. ROE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 67. ROE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 68. ROE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 69. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 70. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 71. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 72. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 73. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 74. CHINA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 75. CHINA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 76. CHINA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 77. CHINA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 78. INDIA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 79. INDIA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 80. INDIA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 81. INDIA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 82. JAPAN BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 83. JAPAN BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 84. JAPAN BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 85. JAPAN BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 86. REST OF APAC BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 87. REST OF APAC BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 88. REST OF APAC BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 89. REST OF APAC BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 90. LATIN AMERICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 91. LATIN AMERICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 92. LATIN AMERICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 93. LATIN AMERICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 94. BRAZIL BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 95. BRAZIL BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 96. BRAZIL BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 97. BRAZIL BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 98. ARGENTINA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 99. ARGENTINA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 100. ARGENTINA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 101. ARGENTINA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 102. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 103. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 104. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 105. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 106. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 107. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 108. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 109. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 110. UAE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 111. UAE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 112. UAE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 113. UAE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 114. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 115. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 116. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 117. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 118. GE HEALTHCARE: FINANCIALS
TABLE 119. GE HEALTHCARE: PRODUCTS & SERVICES
TABLE 120. GE HEALTHCARE: RECENT DEVELOPMENTS
TABLE 121. BIO-RAD LABORATORIES: FINANCIALS
TABLE 122. BIO-RAD LABORATORIES: PRODUCTS & SERVICES
TABLE 123. BIO-RAD LABORATORIES: RECENT DEVELOPMENTS
TABLE 124. EISAI CO. LTD.: FINANCIALS
TABLE 125. EISAI CO. LTD.: PRODUCTS & SERVICES
TABLE 126. EISAI CO. LTD.: RECENT DEVELOPMENTS
TABLE 127. ABBOTT LABORATORIES, INC.: FINANCIALS
TABLE 128. ABBOTT LABORATORIES, INC.: PRODUCTS & SERVICES
TABLE 129. ABBOTT LABORATORIES, INC.: RECENT DEVELOPMENTS
TABLE 130. THERMO FISHER SCIENTIFIC INC.: FINANCIALS
TABLE 131. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES
TABLE 132. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
TABLE 133. AGILENT TECHNOLOGIES INC.: FINANCIALS
TABLE 134. AGILENT TECHNOLOGIES INC.: PRODUCTS & SERVICES
TABLE 135. AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS
TABLE 136. ROCHE DIAGNOSTICS LIMITED: FINANCIALS
TABLE 137. ROCHE DIAGNOSTICS LIMITED: PRODUCTS & SERVICES
TABLE 138. ROCHE DIAGNOSTICS LIMITED: DEVELOPMENTS
TABLE 139. AUSHON BIOSYSTEM: FINANCIALS
TABLE 140. AUSHON BIOSYSTEM: PRODUCTS & SERVICES
TABLE 141. AUSHON BIOSYSTEM: RECENT DEVELOPMENTS
TABLE 142. EPISTEM LTD.: FINANCIALS
TABLE 143. EPISTEM LTD.: PRODUCTS & SERVICES
TABLE 144. EPISTEM LTD.: RECENT DEVELOPMENTS
TABLE 145. SIEMENS AG: FINANCIALS
TABLE 146. SIEMENS AG: PRODUCTS & SERVICES
TABLE 147. SIEMENS AG: RECENT DEVELOPMENTS

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

IHR Insights社のバイオ技術分野での最新刊レポート

本レポートと同じKEY WORD（biomarkers）の最新刊レポート


よくあるご質問


IHR Insights社はどのような調査会社ですか?


IHR InsightsはICT、化学品、ヘルスケア、半導体など、世界の幅広い分野を対象に調査し、専門的な知識を基に市場調査報告書を出版しています。 主な調査分野 ◇ICT ◇化学品、材料、... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21　10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.